The Place of FDG PET/CT in Renal Cell Carcinoma: Value and Limitations

Fletcher, 2008, Recommendations on the use of 18F-FDG PET in oncology, J Nucl Med, 49, 480, 10.2967/jnumed.107.047787

Rohren, 2004, Clinical applications of PET in oncology, Radiology, 231, 302, 10.1148/radiol.2312021185

Kapoor, 2004, An introduction to PET-CT imaging, Radiographics, 24, 523, 10.1148/rg.242025724

Antoch, 2004, Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-d-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET, J Clin Oncol, 22, 4357, 10.1200/JCO.2004.08.120

Pelosi, 2004, Value of integrated PET/CT for lesion localization in cancer patients: a comparative study, Eur J Nucl Med Mol Imaging, 31, 932, 10.1007/s00259-004-1483-3

Reinartz, 2004, Side-by-side reading of PET and CT scans in oncology: which patients might profit from integrated PET/CT?, Eur J Nucl Med Mol Imaging, 31, 1456, 10.1007/s00259-004-1593-y

Delbeke, 2001, Positron emission tomography imaging in oncology, Radiol Clin North Am, 39, 883, 10.1016/S0033-8389(05)70319-5

Liu, 2010, Physiology and pathophysiology of incidental findings detected on FDG-PET scintigraphy, Semin Nucl Med, 40, 294, 10.1053/j.semnuclmed.2010.02.002

Wang, 2012, Meta-analysis of the diagnostic performance of [18F] FDG-PET and PET/CT in renal cell carcinoma, Cancer Imaging, 12, 464, 10.1102/1470-7330.2012.0042

Kamel, 2006, Forced diuresis improves the diagnostic accuracy of 18F-FDG PET in abdominopelvic malignancies, J Nucl Med, 47, 1803

Miyakita, 2002, Significance of 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) for detection of renal cell carcinoma and immunohistochemical glucose transporter 1 (GLUT-1) expression in the cancer, Int J Urol, 9, 15, 10.1046/j.1442-2042.2002.00416.x

Aide, 2003, Efficiency of [(18)F]FDG PET in characterizing renal cancer and detecting distant metastases: a comparison with CT, Eur J Nucl Med Mol Imaging, 30, 1236, 10.1007/s00259-003-1211-4

Kang, 2004, Clinical use of fluorodeoxyglucose F 18 positron emission tomography for detection of renal cell carcinoma, J Urol, 171, 1806, 10.1097/01.ju.0000120241.50061.e4

Ozulker, 2011, A prospective diagnostic accuracy study of F-18 fluorodeoxyglucose-positron emission tomography/computed tomography in the evaluation of indeterminate renal masses, Nucl Med Commun, 32, 265, 10.1097/MNM.0b013e3283442e3b

Kumar, 2005, 2-Deoxy-2-[F-18]fluoro-d-glucose-positron emission tomography in characterization of solid renal masses, Mol Imaging Biol, 7, 431, 10.1007/s11307-005-0026-z

Nakhoda, 2013, Assessment of the diagnostic performance of (18)F-FDG-PET/CT for detection and characterization of solid renal malignancies, Hell J Nucl Med, 16, 19, 10.1967/s002449910067

Takahashi, 2015, Preoperative evaluation of renal cell carcinoma by using 18F-FDG PET/CT, Clin Nucl Med, 40, 936, 10.1097/RLU.0000000000000875

Namura, 2010, Impact of maximum standardized uptake value (SUVmax) evaluated by 18-Fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography (18F-FDG-PET/CT) on survival for patients with advanced renal cell carcinoma: a preliminary report, BMC Cancer, 10, 667, 10.1186/1471-2407-10-667

Ferda, 2013, 18F-FDG-PET/CT in potentially advanced renal cell carcinoma: a role in treatment decisions and prognosis estimation, Anticancer Res, 33, 2665

Lee, 2014, Can initial (18)F-FDG PET-CT imaging give information on metastasis in patients with primary renal cell carcinoma?, Nucl Med Mol Imaging, 48, 144, 10.1007/s13139-013-0245-1

Figlin, 1999, Renal cell carcinoma: management of advanced disease, J Urol, 161, 381, 10.1016/S0022-5347(01)61897-4

Majhail, 2003, F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma, J Clin Oncol, 21, 3995, 10.1200/JCO.2003.04.073

Nakatani, 2011, The potential clinical value of FDG-PET for recurrent renal cell carcinoma, Eur J Radiol, 79, 29, 10.1016/j.ejrad.2009.11.019

Kumar, 2010, Role of FDG PET-CT in recurrent renal cell carcinoma, Nucl Med Commun, 31, 844, 10.1097/MNM.0b013e32833d6882

Bertagna, 2013, Role of F18-FDG-PET/CT in restaging patients affected by renal carcinoma, Nucl Med Rev Cent East Eur, 16, 3, 10.5603/NMR.2013.0002

Fuccio, 2014, Restaging clear cell renal carcinoma with 18F-FDG PET/CT, Clin Nucl Med, 39, e320, 10.1097/RLU.0000000000000382

Win, 2015, Clinical effectiveness of (18)f-fluorodeoxyglucose positron emission tomography/computed tomography in management of renal cell carcinoma: a single institution experience, World J Nucl Med, 14, 36, 10.4103/1450-1147.150535

Alongi, 2016, Recurrent renal cell carcinoma: clinical and prognostic value of FDG PET/CT, Eur J Nucl Med Mol Imaging, 43, 464, 10.1007/s00259-015-3159-6

Sharma, 2012, Imaging thrombus in cancer patients with FDG PET-CT, Jpn J Radiol, 30, 95, 10.1007/s11604-011-0016-9

Sharma, 2011, 18F-FDG PET-CT in the diagnosis of tumor thrombus: can it be differentiated from benign thrombus?, Nucl Med Commun, 32, 782, 10.1097/MNM.0b013e32834774c8

Ravina, 2014, Tumor thrombus: ancillary findings on FDG PET/CT in an oncologic population, Clin Nucl Med, 39, 767, 10.1097/RLU.0000000000000451

Wu, 2002, Comparing whole body 18F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphate bone scan to detect bone metastases in patients with renal cell carcinomas – a preliminary report, J Cancer Res Clin Oncol, 128, 503, 10.1007/s00432-002-0370-1

Rodriguez Martinez de Llano, 2010, Clinical impact of (18)F-FDG PET in management of patients with renal cell carcinoma, Rev Esp Med Nucl, 29, 12, 10.1016/j.remn.2009.11.008

Park, 2009, Significance of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for the postoperative surveillance of advanced renal cell carcinoma, BJU Int, 103, 615, 10.1111/j.1464-410X.2008.08150.x

Jonasch, 2010, Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis, Cancer, 116, 57, 10.1002/cncr.24685

Procopio, 2011, Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial, Br J Cancer, 104, 1256, 10.1038/bjc.2011.103

Chen, 2013, FDG-PET as a predictive biomarker for therapy with everolimus in metastatic renal cell cancer, Cancer Med, 2, 545, 10.1002/cam4.102

Caldarella, 2014, The role of fluorine-18-fluorodeoxyglucose positron emission tomography in evaluating the response to tyrosine-kinase inhibitors in patients with metastatic primary renal cell carcinoma, Radiol Oncol, 48, 219, 10.2478/raon-2013-0067

Kayani, 2011, Sequential FDG-PET/CT as a biomarker of response to Sunitinib in metastatic clear cell renal cancer, Clin Cancer Res, 17, 6021, 10.1158/1078-0432.CCR-10-3309

Lyrdal, 2009, Evaluation of sorafenib treatment in metastatic renal cell carcinoma with 2-fluoro-2-deoxyglucose positron emission tomography and computed tomography, Nucl Med Commun, 30, 519, 10.1097/MNM.0b013e32832cc220

Kakizoe, 2014, The early response of renal cell carcinoma to tyrosine kinase inhibitors evaluated by FDG PET/CT was not influenced by metastatic organ, BMC Cancer, 14, 390, 10.1186/1471-2407-14-390

Ljungberg, 2007, Renal cell carcinoma guideline, Eur Urol, 51, 1502, 10.1016/j.eururo.2007.03.035

Boellaard, 2015, FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0, Eur J Nucl Med Mol Imaging, 42, 328, 10.1007/s00259-014-2961-x

Escudier, 2014, Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 25, iii49, 10.1093/annonc/mdu259

Bouchelouche, 2015, PET/computed tomography in renal, bladder, and testicular cancer, PET Clin, 10, 361, 10.1016/j.cpet.2015.03.002